BOSTON, June 18, 2025 /PRNewswire/ -- HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of oral, small molecule allosteric therapies targeting Smart Allostery platform-identified regulatory sites on proteins referred to as "natural hotspots," today announced it will present preclinical data from the Company's interferon regulatory factor 5 (IRF5) program in an oral and poster presentation at the 25th Annual Meeting of the Federation of Clinical Immunology Societies (FOCIS 2025), taking place June 24-27, 2025, in Boston, MA.
Presentation details are as follows:
Title: Targeting IRF5: Discovery and Preclinical Development of Selective Small Molecule Inhibitors
Session: Late-Breaking Abstracts
Session Date and Time: Wed., Jun. 25, 3:15-5:15 PM ET
Presentation Time: 4:00-4:15 PM ET
Location: Salons H-K, Boston Marriott Copley Place, Boston, MA
About HotSpot Therapeutics, Inc.
HotSpot Therapeutics, Inc. is a clinical-stage biotechnology company that is pioneering a new class of allosteric drugs that target certain naturally occurring pockets on proteins called "natural hotspots." These pockets are decisive in controlling a protein's cellular function and have significant potential for new drug discovery by enabling the systematic design of potent and selective small molecules with novel pharmacology. The Company's proprietary Smart Allostery™ platform combines computational approaches and AI-driven data mining of large and diverse data sets to uncover hotspots with tailored pharmacology toolkits and bespoke chemistry to drive the rapid discovery of novel hotspot-targeted small molecules. Leveraging this approach, HotSpot is building a broad pipeline of novel allosteric therapies for the treatment of autoimmune diseases and cancer. To learn more, visit www.hotspotthera.com.
HotSpot Investor & Media Contact:
Natalie Wildenradt
nwildenradt@hotspotthera.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/hotspot-therapeutics-to-present-preclinical-data-from-small-molecule-irf5-program-at-focis-2025-302484574.html
SOURCE HotSpot Therapeutics
